WHO vaccine-preventable diseases: monitoring system. 2014 global summary

Last updated 15-Jul-2014 (Data received as of 8-Jul-2014)
Next overall update Fall 2014
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 10'7001 Infant (under 12 months) mortality rate: 162
GDP / capita (US$): 19'4111 Child (under 5 years) mortality rate: 182

Population data in thousands3

  2013  2012  2011  2010  2009  2000  1990  1980 
Total population 3'864  3'802  3'740  3'678  3'616  3'055  2'487  1'990 
Births 75  75  75  75  75  73  65  62 
Surviving infants 74  74  74  74  74  71  64  59 
Pop. less than 5 years 369  369  369  368  368  348  312  290 
Pop. less than 15 years 1'094  1'090  1'085  1'078  1'072  981  892  813 
Female 15-49 years 995  980  965  950  936  797  631  468 

Number of reported case

(Click for retrospective incidence data for Panama)
Diphtheria
Japanese encephalitis
Measles 1'891  2'096 
Mumps 165  134  111  81  154  303 
Pertussis 42  47  36  22  101  66  19  641 
Polio*
Rubella 580 
Rubella (CRS)
Tetanus (neonatal) 19 
Tetanus (total) 10  10  31 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Panama)
Vaccine year result method % card seen                                                
BCG          94  99*  100  99*  99*  99*  97  100 
DTP1          93  99  99*  99*  95  99* 
DTP3          80  85  87  94  85  98  86  70 
HepB_BD          79  87  93  89  78 
HepB3          80  85  87  94  85 
Hib3          80  85  87  94  85 
JapEnc         
MCV          92  98  97  99*  85  97  73  71 
MCV2          68  72  81  73  99  88 
PCV1          92  99*  89  99*  20 
PCV3          47  63  48 
Pol3          80  87  91  95  85  99  86  70 
Rota1          93  100  100  99*  97 
Rota_last          87  92  95  89  78 
Rubella1          92  98  97  99*  85 
TT2plus          100  100  99*  99*  98  32  16 
PAB         
VAD1          44  30  10  82 
YFV          52  99*  78  99*  99* 
  ° indicates that more than 1 survey occurred that year

  Next update: July 2015

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Panama)
BCG 95  98  99  99  99  99  97  99 
DTP1 93  99  98  96  95  99  95  72 
DTP3 80  85  87  94  85  98  86  47 
HepB3 80  85  87  94  85 
HepB_BD 79  87  93  89  78 
Hib3 80  85  87  94  85 
MCV 92  98  97  97  96  97  73  71 
MCV2 68  72  81  73  76  88 
PCV3 48  48  48  48 
Pol3 81  87  91  95  85  99  86  70 
Rota_last 87  92  95  89  78 
YFV

Number of districts in the country 79  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 33
From 80 to 89% 35
From 50 to 79% 30
Less than 50% 1
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2013 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DT <5 years; Yes allergic to perussis
DTwP 4 years; Yes
DTwPHib 18 months; Yes
DTwPHibHep 2, 4, 6 months; Yes
HPV 10 years; +1, +6 months; Yes
HepA 12, 18 months; Yes
HepB birth; Yes Also adolescents and HCW
IPV 2, 4, 6, 15 months; 4 years; Yes immunosuppressed
Influenza 6, 8 months; >60 years; Yes PW, HCW and risk groups
MMR 12 months; 4 years; Yes
MR >19 years; Yes CBAW, Postpartum and general population not vaccinated with MMR before.
OPV 2, 4, 6, 18 months; 4 years; Yes
Pneumo_conj 2, 4, 12 months; Yes and risk groups
Pneumo_ps > 60 years; Yes
Rabies Yes Post exposure
Rotavirus 2, 4 months Yes
Td Yes general population and risk groups
Tdap 10 years; Yes And risk groups, postpartum and HCW
Varicella 15, 18 months; Yes outbreaks
VitaminA 1 year; Yes and postpartum
YF 1, 10 year; No high risk areas

Immunizaton indicators

Indicator Expected answer 2013  2012  2011  2010  2009  2008  2007 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  No  No  No  No  Yes 
What years does the MYP cover? number   2'015    2'010       
Nº of districts with microplans that include activities to raise immunization coverage number 79  14  17  76  77  76  76 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes       

System performance

Total Nº districts in country number 79  77  77  76  77  76  76 
Nº districts with DTP3 coverage >=80% number 54  67  58  76  57  61  22 
% of districts with DTP3 coverage >=80% From 0 to 100% 68  87  75  100  74  80  29 
Nº districts with measles (MCV1) coverage >=95% number 34  39  56  63  29  75   
% of districts with MCV1 coverage >=95% From 0 to 100% 43  51  73  83  38  99   

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  Yes  No  Yes       
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Estimated percentage of routine vaccines funded by Government From 0 to 100% 100  100  100  100  100  100   

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.